Page 3 - EADS Scientific Magazine .... 2nd Edition

Management of Hemophilia
Management of Hemophilia

hemo
-
ild or Moderate hemo- 1

treated
Mphilia can be treated

by DDAVP it causes endog-endog-

enous factor VIII, vWF, and
and

plasminogen activator to be

released from storage sites

on the vascular endothelium

and raises FVIII levels three

to six times baseline levels , the dose should
the dose should

be given approximately each 12-hour to pre-to pre-

vent late bleeding from surgical wounds.

2 The other choice is to use

Antifibrinolytic therapy, as tranexamic

acid, inhibits endothelial activators

from binding to fibrin. it is effective

alone or combined with DDAVP.

In case of severe hemophilia or in those patients

unresponsive to DDAVP we should use a re-

placement therapy with plasma-derived or re-

combinant FVIII or FIX and factor replacement